|
EIF3J expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.0325074129014E-14 |
| Normal-vs-Stage2 |
1.53799999957904E-07 |
| Normal-vs-Stage3 |
1.4432899320127E-15 |
| Normal-vs-Stage4 |
1.63191682389652E-12 |
| Stage1-vs-Stage2 |
6.671400E-01 |
| Stage1-vs-Stage3 |
2.248400E-02 |
| Stage1-vs-Stage4 |
2.028300E-02 |
| Stage2-vs-Stage3 |
7.023700E-02 |
| Stage2-vs-Stage4 |
4.057900E-02 |
| Stage3-vs-Stage4 |
6.244600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.4109999999512E-06 |
| Normal-vs-Asian |
1.40750000543477E-09 |
| Caucasian-vs-AfricanAmerican |
5.030400E-01 |
| Caucasian-vs-Asian |
6.071400E-01 |
| AfricanAmerican-vs-Asian |
8.141000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.88578058618805E-15 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
1.165560E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.80266912508387E-12 |
| Normal-vs-Age(41-60Yrs) |
8.88178419700125E-16 |
| Normal-vs-Age(61-80Yrs) |
1.86373139143825E-12 |
| Normal-vs-Age(81-100Yrs) |
2.02129999999912E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.255800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.186200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.580800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.545000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.122800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.696000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.207790E-01 |
| Classical-VS-Follicular |
7.121600E-01 |
| Classical-VS-Other |
2.182400E-01 |
| Classical-VS-Normal |
1.62470037423645E-12 |
| Tall-VS-Follicular |
1.153160E-01 |
| Tall-VS-Other |
6.807600E-01 |
| Tall-VS-Normal |
1.13099973830799E-10 |
| Follicular-VS-Other |
3.215000E-01 |
| Follicular-VS-Normal |
4.57649995677656E-09 |
| Other-VS-Normal |
4.43599999999655E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.44249065417534E-14 |
| Normal-vs-N1 |
6.85118628496184E-13 |
| N0-vs-N1 |
1.526970E-01 |
|
|
